Inhibition of bone resorption by divided-dose calcium supplementation in early postmenopausal women.
We have previously shown that a calcium (Ca) supplement of 1000 mg given in the evening reduces the overnight and early morning, but not the daytime, excretion of bone resorption markers in postmenopausal women within five years of the menopause. In the present study, we have looked at the effect of splitting the Ca into two doses of 500 mg each given in the morning and evening. We studied 19 healthy women (median age 53 years) who were all within 5 years of the menopause. On the 2 study days, urine was collected from 9 a.m. to 9 p.m. (day collection), and from 9 p.m. to 9 a.m. (night collection); a further fasting (spot) urine sample was obtained at 9 a.m. at the end of the night collection. The first day was a control day; on the second day the subjects ingested 500 mg Ca as the carbonate at 9 a.m. and 9 p.m. We measured pyridinoline cross-links excretion in all the samples, as well as hydroxyproline in the fasting urine. The Ca supplements lowered urinary excretion of the markers during the day (P < 0.01), had only a marginal effect during the night, but reduced excretion significantly in the fasting urine (P < 0.001). In the whole 24-hour period, the falls in resorption markers were small but comparable to those seen after the ingestion of 1 g of Ca in the evening. We conclude that the acute administration of 0.5 g Ca in the morning and evening reduced the markers of bone resorption in early postmenopausal women during the day but not during the following night, whereas the single 1 g supplement had the reverse effect. Over the 24-hour period, there was nothing to choose between the two regimes. Women at this stage in their life cycle probably require a larger Ca supplement if they are not taking estrogen.
Scopacasa
F
F
Division of Clinical Biochemistry, Institute of Medical and Veterinary Science, University of Adelaide, Royal Adelaide Hospital, Australia.
Need
A G
AG
Horowitz
M
M
Wishart
J M
JM
Morris
H A
HA
Nordin
B E
BE
D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000652:urine; D001862:Bone Resorption / Q000517:prevention & control* / Q000652:urine; D002118:Calcium / Q000008:administration & dosage*; D019587:Dietary Supplements; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control* / Q000652:urine; D013997:Time Factors
D000596:Amino Acids; D015415:Biomarkers; C015484:pyridinoline; D006909:Hydroxyproline; D002118:Calcium